Trial intelligence / Profile preview

Prevenar 13 vs Pneumovax in Untreated CLL

NCT01892618Phase 3Completed

Sponsor
Karolinska University Hospital
Start
Aug 2013
Primary completion
Dec 2015
Modality
Split/Subunit Vaccines
Countries
1
01

Overview

A Phase 3 trial of pneumococcal 13-valent conjugate vaccine in pneumococcal disease, sponsored by Karolinska University Hospital. Started Aug 2013; status: completed.

02

Drugs

pneumococcal 13-valent conjugate vaccine
03

Conditions

pneumococcal disease

Beyond the preview

Go deeper on NCT01892618.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT01892618.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call